Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid. 1995

K L Bourantas, and S Tsiara, and L Christou
Department of Internal Medicine, University of Ioannina, Greece.

Thirty-four patients with myelodysplastic syndromes, 23 men and 11 women, aged between 47 and 80 years, with all types of myelodysplastic syndromes were treated with 13-cis-retinoic acid. The dose of retinoic acid ranged between 10 and 60 mg/m2/daily and was administered in combination with vitamin E to diminish side effects. The duration of treatment was 3 months to 5 years. Partial remission was achieved in 4 patients, 1 with RA type, 2 with RAEB and 1 with CMML. Survival ranged from 1 to 5 years. Patients who received retinoic acid developed mild side effects. In conclusion, the administration of 13-cis-retinoic acid improves the hematological picture in a small number of MDS patients (11.7%).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000753 Anemia, Refractory A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy. Refractory Anemia,Anemias, Refractory,Refractory Anemias
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014810 Vitamin E A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.
D015474 Isotretinoin A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects. 13-cis-Retinoic Acid,Accutane,Isotretinoin Zinc Salt, 13-cis-Isomer,Ro 4-3780,Roaccutane,13 cis Retinoic Acid,Isotretinoin Zinc Salt, 13 cis Isomer,Ro 4 3780,Ro 43780

Related Publications

K L Bourantas, and S Tsiara, and L Christou
January 1987, Leukemia research,
K L Bourantas, and S Tsiara, and L Christou
April 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K L Bourantas, and S Tsiara, and L Christou
August 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K L Bourantas, and S Tsiara, and L Christou
January 1988, Acta haematologica,
K L Bourantas, and S Tsiara, and L Christou
January 1986, Scandinavian journal of haematology. Supplementum,
K L Bourantas, and S Tsiara, and L Christou
November 1983, Cancer treatment reports,
K L Bourantas, and S Tsiara, and L Christou
January 1987, Leukemia research,
K L Bourantas, and S Tsiara, and L Christou
April 1987, Lancet (London, England),
Copied contents to your clipboard!